Higher-concentration intranasal naloxone has similar efficacy to that of intramuscular naloxone given at the same dose for reversal of opioid overdose.
There is a significantly increased risk of prescription opioid deaths for those born between 1947 and 1964.
There may be more health benefits at a lower cost with immediate access to opioid agonist treatment for patients with opioid use disorder.
There is a higher risk for opioid-related death in patients taking concomitant prescription opioids and gabapentin.
Medicare Part D formularies increasingly used quantity limits and prior authorization in order to reduce dosing of prescription opioids.
After surgical procedures, the optimal length of opioid prescription lies between the observed median prescription length and the early nadir.
The CDC is is launching a campaign to help fight the opioid crisis.
It is recommended that physicians educate their patients/their patients' family members regarding the steps to take in case of a potential overdose.
The most opioid use occurs in the top 10% of privately insured adults without cancer who are using opioids.
Assessments showed a 66% reduction in pain during the session and a 33% reduction in pain at the end of the session.
There are nearly as many migraine patients receiving opioids as there are patients receiving level A abortive medications.
There is an increased risk of neonatal drug withdrawal if psychotropic medications and opioids are used during pregnancy.
As a response to the opioid epidemic, clinicians may be overprescribing gabapentinoids.
Even though there are concerns about opioid addiction and misuse, there are still more than 1/3 of Americans using them.
Quality of life and improved pain and function may be achieved by reducing opioid doses.
Hospitalists must use opioids judiciously, including adhering to specific dose limits and setting expectations for pain control, medication stop dates, and refills.
Most prescriptions for long-term opioid therapy were written by internal or family medicine physicians.
Patients with chronic pain may have a lower risk of becoming addicted to opioids if they are taught coping skills.
The NASEM report, which was commissioned by the FDA, gives an update on current research in the pain field.
An FDA panel previously voted that the drug's benefits no longer outweigh its risks.
Sublingual buprenorphine was associated with shorter duration of treatment and shorter length of hospital stay.
The VA and DoD issue a clinical practice guideline regarding opioid therapy for chronic pain in veterans.
New research suggests that opioid addiction may be linked to a genetic variant, and more personalized treatment may help those with the change.
The abuse of opioids or other substances may cause short-term amnesia.
Patients with successful spinal cord stimulation implants had significantly reduced opioid use 1 year post-implant.
The FDA instituted widespread updates to product labeling for opioid medications in December, 2016.
Kratom may be used to develop nonaddictive alternatives to opioids.
Opioid usage may exacerbate the problem.
Clinicians need to remain vigilant when prescribing tramadol, as its concurrent use with opioids poses a risk of serotonin toxicity.
Patients who underwent thoracic surgery were at the greatest risk of long-term opioid use.
Neurology Advisor Articles
- Brainstem Damage in Epilepsy May Be Biomarker for Increased SUDEP Risk
- Increased Epilepsy Risk Identified in Multiple Sclerosis
- Distinct Clinical Characteristics Associated With Subarachnoid Hemorrhage
- Managing Chronic Pain Associated With Traumatic Brain Injury
- Prognostic Significance of Weight Loss in Patients With Early Parkinsonism
- Coffee Consumption May Decrease Stroke Risk
- When and How to Approach Driving Cessation in Patients With Dementia
- NBT System Gets FDA Clearance for Depression Treatment
- Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- McDonald Criteria Update: Further Distinction Between Relapsing-Remitting, Primary-Progressive MS
- Initial Treatment With Ethosuximide Improves Behavioral Outcomes in Childhood Absence Epilepsy
- Bivacizumab Wins Full FDA Approval for Glioblastoma Treatment
- Men With Parkinson Disease More Likely to Have Caregiver
- Diet Linked to Multiple Sclerosis Disability, Diseases Severity